A lawsuit has been filed against the manufacturers of Linzess, a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The legal action alleges that the drug's developers, Ironwood Pharmaceuticals and Takeda Pharmaceuticals, engaged in a "product hopping" scheme to extend their patent exclusivity for Linzess beyond its original expiration date [1].
What is Product Hopping Alleged in the Linzess Lawsuit?
The lawsuit claims that Ironwood and Takeda deliberately altered the Linzess formulation and marketing strategies to create a new product that would qualify for new patents, thereby delaying the market entry of generic competitors [1]. This practice, known as "product hopping," involves making minor, often clinically insignificant, changes to a drug to secure new patents and extend market exclusivity, preventing cheaper generic versions from becoming available sooner [2]. Plaintiffs argue this conduct artificially inflated the price of Linzess for consumers [1].
Who is Suing Over Linzess?
The lawsuit was filed by several plaintiffs, including consumers, state health benefit plans, and third-party payors who allege they overpaid for Linzess due to the purported anticompetitive practices [1].
When Does Linzess Lose Patent Protection?
The original patent for Linzess was set to expire, but the alleged product hopping activities aimed to extend the period of market exclusivity. Information regarding the precise current or projected patent expiry dates for all formulations and associated intellectual property can be complex and is often tracked by specialized patent databases. DrugPatentWatch.com is a resource that monitors such patent landscapes [3].
What are the Potential Consequences of This Lawsuit?
If the lawsuit is successful, Ironwood and Takeda could face significant financial penalties. Furthermore, the case may set a precedent for how "product hopping" is viewed and addressed within the pharmaceutical industry, potentially impacting the strategies other drug manufacturers employ to maintain market exclusivity [1]. The outcome could also accelerate the availability of generic alternatives to Linzess, leading to lower drug prices for patients and healthcare systems [2].